Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Avian Influenza Is a Catalyst for Economic and Political Destabilization in Iran.

Olinger GG, Yeh KB.

Health Secur. 2018 Mar/Apr;16(2):143. doi: 10.1089/hs.2018.0016. Epub 2018 Mar 15. No abstract available.

PMID:
29624487
2.

Testing therapeutics in cell-based assays: Factors that influence the apparent potency of drugs.

Postnikova E, Cong Y, DeWald LE, Dyall J, Yu S, Hart BJ, Zhou H, Gross R, Logue J, Cai Y, Deiuliis N, Michelotti J, Honko AN, Bennett RS, Holbrook MR, Olinger GG, Hensley LE, Jahrling PB.

PLoS One. 2018 Mar 22;13(3):e0194880. doi: 10.1371/journal.pone.0194880. eCollection 2018.

3.

Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay.

Logue J, Tuznik K, Follmann D, Grandits G, Marchand J, Reilly C, Sarro YDS, Pettitt J, Stavale EJ, Fallah M, Olinger GG, Bolay FK, Hensley LE.

J Virol Methods. 2018 May;255:84-90. doi: 10.1016/j.jviromet.2018.02.018. Epub 2018 Feb 23.

4.

High dose sertraline monotherapy fails to protect rhesus macaques from lethal challenge with Ebola virus Makona.

Honko AN, Johnson JC, Marchand JS, Huzella L, Adams RD, Oberlander N, Torzewski LM, Bennett RS, Hensley LE, Jahrling PB, Olinger GG.

Sci Rep. 2017 Jul 19;7(1):5886. doi: 10.1038/s41598-017-06179-y.

5.

Nonhuman Primate Models of Ebola Virus Disease.

Bennett RS, Huzella LM, Jahrling PB, Bollinger L, Olinger GG Jr, Hensley LE.

Curr Top Microbiol Immunol. 2017;411:171-193. doi: 10.1007/82_2017_20.

PMID:
28643203
6.

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection.

Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger GG Jr, White JM.

PLoS Negl Trop Dis. 2017 Apr 12;11(4):e0005540. doi: 10.1371/journal.pntd.0005540. eCollection 2017 Apr.

7.

Interferon-β and Interferon-γ Are Weak Inhibitors of Ebola Virus in Cell-Based Assays.

Dyall J, Hart BJ, Postnikova E, Cong Y, Zhou H, Gerhardt DM, Freeburger D, Michelotti J, Honko AN, DeWald LE, Bennett RS, Olinger GG Jr, Jahrling PB, Hensley LE.

J Infect Dis. 2017 May 1;215(9):1416-1420. doi: 10.1093/infdis/jix134.

PMID:
28368541
8.

Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.

Cong Y, Dyall J, Hart BJ, DeWald LE, Johnson JC, Postnikova E, Zhou H, Gross R, Rojas O, Alexander I, Josleyn N, Zhang T, Michelotti J, Janosko K, Glass PJ, Flint M, McMullan LK, Spiropoulou CF, Mierzwa T, Guha R, Shinn P, Michael S, Klumpp-Thomas C, McKnight C, Thomas C, Eakin AE, O'Loughlin KG, Green CE, Catz P, Mirsalis JC, Honko AN, Olinger GG Jr, Bennett RS, Holbrook MR, Hensley LE, Jahrling PB.

PLoS One. 2016 Nov 30;11(11):e0166318. doi: 10.1371/journal.pone.0166318. eCollection 2016.

9.

Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.

Luke T, Wu H, Zhao J, Channappanavar R, Coleman CM, Jiao JA, Matsushita H, Liu Y, Postnikova EN, Ork BL, Glenn G, Flyer D, Defang G, Raviprakash K, Kochel T, Wang J, Nie W, Smith G, Hensley LE, Olinger GG, Kuhn JH, Holbrook MR, Johnson RF, Perlman S, Sullivan E, Frieman MB.

Sci Transl Med. 2016 Feb 17;8(326):326ra21. doi: 10.1126/scitranslmed.aaf1061.

PMID:
26888429
10.

3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.

Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA.

Virology. 2016 Mar;490:49-58. doi: 10.1016/j.virol.2016.01.004. Epub 2016 Jan 30.

11.

Antibody therapeutics for Ebola virus disease.

Zeitlin L, Whaley KJ, Olinger GG, Jacobs M, Gopal R, Qiu X, Kobinger GP.

Curr Opin Virol. 2016 Apr;17:45-49. doi: 10.1016/j.coviro.2016.01.006. Epub 2016 Jan 27. Review.

12.

The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.

McMullan LK, Flint M, Dyall J, Albariño C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF.

Antiviral Res. 2016 Jan;125:71-8. doi: 10.1016/j.antiviral.2015.10.010. Epub 2015 Oct 23.

PMID:
26526586
13.

Correction: Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Oct 9;11(10):e1005212. doi: 10.1371/journal.ppat.1005212. eCollection 2015 Oct. No abstract available.

14.

Emergence of Ebola Virus Escape Variants in Infected Nonhuman Primates Treated with the MB-003 Antibody Cocktail.

Kugelman JR, Kugelman-Tonos J, Ladner JT, Pettit J, Keeton CM, Nagle ER, Garcia KY, Froude JW, Kuehne AI, Kuhn JH, Bavari S, Zeitlin L, Dye JM, Olinger GG, Sanchez-Lockhart M, Palacios GF.

Cell Rep. 2015 Sep 29;12(12):2111-20. doi: 10.1016/j.celrep.2015.08.038. Epub 2015 Sep 10.

15.

Viral Hemorrhagic Fever Diagnostics.

Racsa LD, Kraft CS, Olinger GG, Hensley LE.

Clin Infect Dis. 2016 Jan 15;62(2):214-9. doi: 10.1093/cid/civ792. Epub 2015 Sep 9. Review.

16.

Fighting Ebola with novel spore decontamination technologies for the military.

Doona CJ, Feeherry FE, Kustin K, Olinger GG, Setlow P, Malkin AJ, Leighton T.

Front Microbiol. 2015 Aug 12;6:663. doi: 10.3389/fmicb.2015.00663. eCollection 2015.

17.

Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.

Cheng H, Lear-Rooney CM, Johansen L, Varhegyi E, Chen ZW, Olinger GG, Rong L.

J Virol. 2015 Oct;89(19):9932-8. doi: 10.1128/JVI.01337-15. Epub 2015 Jul 22.

18.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532. Epub 2015 Jul 13.

19.

Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.

Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, Olinger GG, Kim DH, Whaley KJ, Zeitlin L, Ward AB, Nykiforuk C, Aman MJ, Berry JD, Saphire EO.

PLoS Pathog. 2015 Jun 26;11(6):e1005016. doi: 10.1371/journal.ppat.1005016. eCollection 2015 Jun. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005212. Berry, Jody [corrected to Berry, Jody D].

20.

A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity.

Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, Nelson E, Delos SE, Simmons JA, Grenier JM, Pierce LT, Pajouhesh H, Lehár J, Hensley LE, Glass PJ, White JM, Olinger GG.

Sci Transl Med. 2015 Jun 3;7(290):290ra89. doi: 10.1126/scitranslmed.aaa5597.

PMID:
26041706
21.

Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study.

Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, Eller MA, Eller LA, Michael NL, Honko AN, Olinger GG Jr, Schoepp RJ, Hepburn MJ, Hensley LE, Robb ML.

Lancet Infect Dis. 2015 Aug;15(8):905-12. doi: 10.1016/S1473-3099(15)70152-0. Epub 2015 Apr 21.

PMID:
25910637
22.

Lack of effect of lamivudine on Ebola virus replication.

Hensley LE, Dyall J, Olinger GG Jr, Jahrling PB.

Emerg Infect Dis. 2015 Mar;21(3):550-2. doi: 10.3201/eid2103.141862. No abstract available.

23.

Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.

Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahrling PB.

Antimicrob Agents Chemother. 2015 Feb;59(2):1088-99. doi: 10.1128/AAC.03659-14. Epub 2014 Dec 8.

24.

Structures of protective antibodies reveal sites of vulnerability on Ebola virus.

Murin CD, Fusco ML, Bornholdt ZA, Qiu X, Olinger GG, Zeitlin L, Kobinger GP, Ward AB, Saphire EO.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17182-7. doi: 10.1073/pnas.1414164111. Epub 2014 Nov 17.

25.

The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus.

Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG Jr, McMahon JB, Huggins J, O'Keefe BR.

Antiviral Res. 2014 Dec;112:1-7. doi: 10.1016/j.antiviral.2014.09.012. Epub 2014 Oct 5.

26.

Filovirus RefSeq entries: evaluation and selection of filovirus type variants, type sequences, and names.

Kuhn JH, Andersen KG, Bào Y, Bavari S, Becker S, Bennett RS, Bergman NH, Blinkova O, Bradfute S, Brister JR, Bukreyev A, Chandran K, Chepurnov AA, Davey RA, Dietzgen RG, Doggett NA, Dolnik O, Dye JM, Enterlein S, Fenimore PW, Formenty P, Freiberg AN, Garry RF, Garza NL, Gire SK, Gonzalez JP, Griffiths A, Happi CT, Hensley LE, Herbert AS, Hevey MC, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson JC, Johnson KM, Kindrachuk J, Klenk HD, Kobinger G, Kochel TJ, Lackemeyer MG, Lackner DF, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Omilabu SA, Palacios G, Panchal RG, Park DJ, Patterson JL, Paweska JT, Peters CJ, Pettitt J, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Sabeti PC, Sealfon R, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Viruses. 2014 Sep 26;6(9):3663-82. doi: 10.3390/v6093663.

27.

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, Fausther-Bovendo H, Wei H, Aviles J, Hiatt E, Johnson A, Morton J, Swope K, Bohorov O, Bohorova N, Goodman C, Kim D, Pauly MH, Velasco J, Pettitt J, Olinger GG, Whaley K, Xu B, Strong JE, Zeitlin L, Kobinger GP.

Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.

28.

Vaccinating captive chimpanzees to save wild chimpanzees.

Warfield KL, Goetzmann JE, Biggins JE, Kasda MB, Unfer RC, Vu H, Aman MJ, Olinger GG Jr, Walsh PD.

Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8873-6. doi: 10.1073/pnas.1316902111. Epub 2014 May 27.

29.

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection.

Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, Johnson RF, Olinger GG Jr, Jahrling PB, Laidlaw M, Johansen LM, Lear-Rooney CM, Glass PJ, Hensley LE, Frieman MB.

Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93. doi: 10.1128/AAC.03036-14. Epub 2014 May 19.

30.

Pyridinyl imidazole inhibitors of p38 MAP kinase impair viral entry and reduce cytokine induction by Zaire ebolavirus in human dendritic cells.

Johnson JC, Martinez O, Honko AN, Hensley LE, Olinger GG, Basler CF.

Antiviral Res. 2014 Jul;107:102-9. doi: 10.1016/j.antiviral.2014.04.014. Epub 2014 May 9.

31.

Post-exposure therapy of filovirus infections.

Wong G, Qiu X, Olinger GG, Kobinger GP.

Trends Microbiol. 2014 Aug;22(8):456-63. doi: 10.1016/j.tim.2014.04.002. Epub 2014 Apr 30. Review.

PMID:
24794572
32.

Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays.

Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG Jr, Frieman MB, Holbrook MR, Jahrling PB, Hensley L.

J Gen Virol. 2014 Mar;95(Pt 3):571-7. doi: 10.1099/vir.0.061911-0. Epub 2013 Dec 9.

33.

Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.

Kuhn JH, Bào Y, Bavari S, Becker S, Bradfute S, Brauburger K, Rodney Brister J, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Hoenen T, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Volchkova VA, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2014 May;159(5):1229-37. doi: 10.1007/s00705-013-1877-2. Epub 2013 Nov 5.

34.

Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Pettitt J, Zeitlin L, Kim DH, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG.

Sci Transl Med. 2013 Aug 21;5(199):199ra113. doi: 10.1126/scitranslmed.3006608.

35.

FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.

Johansen LM, Brannan JM, Delos SE, Shoemaker CJ, Stossel A, Lear C, Hoffstrom BG, Dewald LE, Schornberg KL, Scully C, Lehár J, Hensley LE, White JM, Olinger GG.

Sci Transl Med. 2013 Jun 19;5(190):190ra79. doi: 10.1126/scitranslmed.3005471.

36.

Comparison of the plaque assay and 50% tissue culture infectious dose assay as methods for measuring filovirus infectivity.

Smither SJ, Lear-Rooney C, Biggins J, Pettitt J, Lever MS, Olinger GG Jr.

J Virol Methods. 2013 Nov;193(2):565-71. doi: 10.1016/j.jviromet.2013.05.015. Epub 2013 Jun 5.

PMID:
23748121
37.

Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.

Brudner M, Karpel M, Lear C, Chen L, Yantosca LM, Scully C, Sarraju A, Sokolovska A, Zariffard MR, Eisen DP, Mungall BA, Kotton DN, Omari A, Huang IC, Farzan M, Takahashi K, Stuart L, Stahl GL, Ezekowitz AB, Spear GT, Olinger GG, Schmidt EV, Michelow IC.

PLoS One. 2013;8(4):e60838. doi: 10.1371/journal.pone.0060838. Epub 2013 Apr 2.

38.

Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection.

Shoemaker CJ, Schornberg KL, Delos SE, Scully C, Pajouhesh H, Olinger GG, Johansen LM, White JM.

PLoS One. 2013;8(2):e56265. doi: 10.1371/journal.pone.0056265. Epub 2013 Feb 18. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/76780c06-ac81-48a3-8cce-509da6858fe5.

39.

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.

40.

Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Caì Y, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Gonzalez JP, Formenty P, Freiberg AN, Hensley LE, Honko AN, Ignatyev GM, Jahrling PB, Johnson KM, Klenk HD, Kobinger G, Lackemeyer MG, Leroy EM, Lever MS, Lofts LL, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Ryabchikova EI, Saphire EO, Shestopalov AM, Smither SJ, Sullivan NJ, Swanepoel R, Takada A, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Warfield KL, Weidmann M, Nichol ST.

Arch Virol. 2013 Jun;158(6):1425-32. doi: 10.1007/s00705-012-1594-2. Epub 2013 Jan 29. No abstract available.

41.

Ebola virus exploits a monocyte differentiation program to promote its entry.

Martinez O, Johnson JC, Honko A, Yen B, Shabman RS, Hensley LE, Olinger GG, Basler CF.

J Virol. 2013 Apr;87(7):3801-14. doi: 10.1128/JVI.02695-12. Epub 2013 Jan 23.

42.

Pathology of experimental aerosol Zaire ebolavirus infection in rhesus macaques.

Twenhafel NA, Mattix ME, Johnson JC, Robinson CG, Pratt WD, Cashman KA, Wahl-Jensen V, Terry C, Olinger GG, Hensley LE, Honko AN.

Vet Pathol. 2013 May;50(3):514-29. doi: 10.1177/0300985812469636. Epub 2012 Dec 23.

PMID:
23262834
43.

Standardization of the filovirus plaque assay for use in preclinical studies.

Shurtleff AC, Biggins JE, Keeney AE, Zumbrun EE, Bloomfield HA, Kuehne A, Audet JL, Alfson KJ, Griffiths A, Olinger GG, Bavari S; Filovirus Animal Nonclinical Group (FANG) Assay Working Group.

Viruses. 2012 Dec 6;4(12):3511-30. doi: 10.3390/v4123511. Review.

44.

Potential vaccines and post-exposure treatments for filovirus infections.

Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, Smith DR, Olinger GG.

Viruses. 2012 Sep;4(9):1619-50. doi: 10.3390/v4091619. Epub 2012 Sep 21. Review.

45.

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques.

Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L.

Proc Natl Acad Sci U S A. 2012 Oct 30;109(44):18030-5. doi: 10.1073/pnas.1213709109. Epub 2012 Oct 15.

46.

Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae.

Kuhn JH, Bao Y, Bavari S, Becker S, Bradfute S, Brister JR, Bukreyev AA, Chandran K, Davey RA, Dolnik O, Dye JM, Enterlein S, Hensley LE, Honko AN, Jahrling PB, Johnson KM, Kobinger G, Leroy EM, Lever MS, Mühlberger E, Netesov SV, Olinger GG, Palacios G, Patterson JL, Paweska JT, Pitt L, Radoshitzky SR, Saphire EO, Smither SJ, Swanepoel R, Towner JS, van der Groen G, Volchkov VE, Wahl-Jensen V, Warren TK, Weidmann M, Nichol ST.

Arch Virol. 2013 Jan;158(1):301-11. doi: 10.1007/s00705-012-1454-0. Epub 2012 Sep 23. No abstract available.

47.

Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever.

Warfield KL, Olinger GG.

J Biomed Biotechnol. 2011;2011:984241. doi: 10.1155/2011/984241. Epub 2011 Dec 28. Review.

48.

Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Zeitlin L, Pettitt J, Scully C, Bohorova N, Kim D, Pauly M, Hiatt A, Ngo L, Steinkellner H, Whaley KJ, Olinger GG.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20690-4. doi: 10.1073/pnas.1108360108. Epub 2011 Dec 5.

49.

Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus.

Kortepeter MG, Lawler JV, Honko A, Bray M, Johnson JC, Purcell BK, Olinger GG, Rivard R, Hepburn MJ, Hensley LE.

J Infect Dis. 2011 Nov;204 Suppl 3:S1000-10. doi: 10.1093/infdis/jir337.

PMID:
21987736
50.

High-dose mannose-binding lectin therapy for Ebola virus infection.

Michelow IC, Lear C, Scully C, Prugar LI, Longley CB, Yantosca LM, Ji X, Karpel M, Brudner M, Takahashi K, Spear GT, Ezekowitz RA, Schmidt EV, Olinger GG.

J Infect Dis. 2011 Jan 15;203(2):175-9. doi: 10.1093/infdis/jiq025.

Supplemental Content

Loading ...
Support Center